Barclays Remains a Hold on Novartis AG (NOVN)
In a report released today, James Gordon CFA from Barclays maintained a Hold rating on Novartis AG, with a price target of CHF120.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to Barclays, Novartis AG also received a Hold from UBS’s Matthew Weston in a report issued yesterday. However, today, Citi maintained a Buy rating on Novartis AG (Six Swiss: NOVN).
Based on Novartis AG’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of CHF14.36 billion and a net profit of CHF3.93 billion. In comparison, last year the company earned a revenue of CHF13.17 billion and had a net profit of CHF3.19 billion
Read More on CH:NOVN:
Disclaimer & DisclosureReport an Issue
- Novartis: Resilient Core Performance and Medium-Term Pipeline Catalysts Support Buy Rating Despite Near-Term Guidance Softness
- Buy Rating on Novartis: Near-Term Guidance Headwinds Outweighed by Resilient Fundamentals, Advancing Pipeline, and Supportive Valuation
- Novartis: Resilient Core Earnings, Conservative Guidance and Robust Pipeline Support Buy Rating and EPS Upside to 2030
- Novartis reports Q4 core EPS $2.03 vs. $1.98 last year
- Novartis sees FY26 net sales up low single digits vs. last year
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.